Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Market Status
  5. Rd
  6. Ind Application

IND Application

Thumbnail
February 13, 2019

Another knock back for urea cycle disorders 

Curevac’s decision to exit work on an mRNA approach to OTC deficiency follows a clinical hold on Translate Bio’s similar project, and raises broader concerns.

Thumbnail
August 06, 2018

Regenerating insulin-producing cells the next big thing in diabetes

Novo Nordisk's cell therapy collaborations are a sign that serious work is under way.

Article image
Vantage logo
July 16, 2018

Better late than never for Maxcyte’s one-day CAR-T approach

Vantage logo
April 11, 2017

Double trouble sinks Oncomed as investors look to earlier assets

Vantage logo
February 16, 2017

Patent twists and turns make Crispr no easier to value

Vantage logo
October 13, 2016

Therapy focus – Curis thinks small to hit big immuno-oncology target

Vantage logo
June 22, 2016

First human Crispr trial is a go, but don’t ask about the IP

Vantage logo
January 28, 2016

Interview – Enterome has a good gut feeling about 2016

Vantage logo
February 25, 2015

Therapeutic focus – Astra goes ROR fishing and hooks Orca

Vantage logo
May 09, 2014

Interview – GW Pharma eyes breakthrough therapy as epilepsy data approach

Vantage logo
November 09, 2009

EP Vantage Interview - ACT heads for the clinic with second stem cell-based therapy

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

August 10, 2022

Q2 Roundup eBook

July 28, 2022

Access Valuable Insights Payer Behaviour Infographic

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.